Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06955156 | Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC | unknown | Phase 2 | 50 | QIAO LIOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04767009 | SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors | unknown | Phase 2 | 59 | Fudan UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05241093 |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| unknown |
| Phase 2 |
| 18 |
| Tarapeutics Science Inc.INDUSTRY |
| 1 |
| Apr 10, 2025 |
| clinicaltrials |
| NCT01885702 | Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | unknown | Phase 1 / Phase 2 | 25 | Radboud University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05504265 | Perioperative Analgesia Modes in Minimally Invasive Esophagectomy | unknown | Phase 2 / Phase 3 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT01903330 | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | unknown | Phase 2 | 84 | Epitopoietic Research CorporationINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT06530511 | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | unknown | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06353061 | Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer | unknown | Phase 2 | 51 | Peking Union Medical College HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT01753414 | Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC(POSTILV) | unknown | Phase 2 | 44 | Radiation Therapy Oncology GroupNETWORK | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06237257 | A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer | unknown | Phase 2 | 56 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06403111 | FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC | unknown | Phase 2 | 62 | Changzhou No.2 People's HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06470672 | Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04551495 | Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)(ROSALINE) | unknown | Phase 2 | 65 | Jules Bordet InstituteOTHER | 2 | Dec 4, 2024 | clinicaltrials |
| NCT06541314 | Fluzoparib Neoadjuvant Therapy for Ovarian Cancer | unknown | Phase 2 | 48 | Qilu Hospital of Shandong UniversityOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06697990 | Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients | unknown | Phase 2 | 12 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 20, 2024 | clinicaltrials |
| NCT06678230 | Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 40 | The First Hospital of Jilin UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05042128 | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma(ASCEND) | unknown | Phase 2 | 158 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | Oct 22, 2024 | clinicaltrials |
| NCT02236910 | An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours | unknown | Phase 2 | 66 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06403709 | Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients | unknown | Phase 2 | 35 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06586697 | First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06590194 | PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 96 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593899 | The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities | unknown | Phase 2 | 51 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06598046 | A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC | unknown | Phase 2 | 48 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06577311 | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | unknown | Phase 2 | 20 | The Center for Clinical and Cosmetic ResearchOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT00080756 | Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease | unknown | Phase 2 | 11 | City of Hope Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05272293 | Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05334693 | Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | unknown | Phase 1 / Phase 2 | 15 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05914662 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM(ZBR) | unknown | Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06574763 | Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer | unknown | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06575127 | Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study | unknown | Phase 2 | 60 | Al-Azhar UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05475184 | A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor | unknown | Phase 2 | 58 | Onconic Therapeutics Inc.INDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT05830097 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 260 | Coherent Biopharma (Hefei) Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT06471673 | A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | unknown | Phase 1 / Phase 2 | 18 | BriaCell Therapeutics CorporationINDUSTRY | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06569459 | Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT05007938 | Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | unknown | Phase 2 | 35 | European Institute of OncologyOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT06149169 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | unknown | Phase 2 | 10 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT03612232 | Cabozantinib in Advanced Adrenocortical Carcinoma(CaboACC) | unknown | Phase 2 | 37 | Wuerzburg University HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06561022 | Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping(abemaSNF1/3) | unknown | Phase 2 | 260 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05182866 | ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer | unknown | Phase 2 | 9 | Rakuten Medical, Inc.INDUSTRY | 1 | Aug 16, 2024 | clinicaltrials |
| NCT03658785 | Immunotherapy for the Treatment of Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04524208 | A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3(CABONEN) | unknown | Phase 2 | 45 | Karsten GavenisOTHER | 2 | Aug 13, 2024 | clinicaltrials |
| NCT05833815 | Addition of Everolimus to Standard of Care in Carcinoma Gallbladder | unknown | Phase 2 / Phase 3 | 56 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 2, 2025source: clinicaltrials